AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
lincomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, produced by Streptomyces strains | 1582 | 154-21-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.80 | g | O |
| 1.80 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 30 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 129.94 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 25 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 2.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 5.60 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,BRAF,CAMK2D,CDK5,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP2K6,MAP3K21,MAPK10,MAPK7,NTRK1,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK,TGFBR1,ZAP70 | 22 | |||
| kinase-selectivity-class | CHUK,MAP2K6,PDK1 | 3 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | High | 0.87 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 29, 1964 | FDA | PHARMACIA AND UPJOHN |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 246.32 | 57.89 | 74 | 157 | 463535 | 90164681 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug hypersensitivity | 164.76 | 43.06 | 54 | 206 | 454036 | 110135003 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01FF02 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS Lincosamides |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D011500 | Protein Synthesis Inhibitors |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:76969 | bacterial metabolite |
Related Drugs by ATC class:
J01FF Lincosamides 1 drug
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Pneumococcal infectious disease | indication | 16814004 | |
| Staphylococcal infectious disease | indication | 56038003 | |
| Streptococcal infectious disease | indication | 85769006 | |
| Disorder of digestive system | contraindication | 53619000 | DOID:77 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Colitis | contraindication | 64226004 | DOID:0060180 |
| Pseudomembranous enterocolitis | contraindication | 397683000 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Bees | Control of American foulbrood (Paenibacillus larvae) | Indication |
| Cats | Infections caused by gram-positive organisms (streptococci and staphylococci) | Indication |
| Chickens | Control of airsacculitis caused by Mycoplasma synoviae | Indication |
| Chickens | Control of airsacculitis caused by Mycoplasma gallisepticum | Indication |
| Chickens | Complicated chronic respiratory disease (air sac infection) | Indication |
| Chickens | Necrotic enteritis caused or complicated by Clostridium spp | Indication |
| Dogs | Infections caused by gram-positive organisms (streptococci and staphylococci) | Indication |
| Swine | Dysentery (bloody scours) | Indication |
| Swine | Infectious arthritis | Indication |
| Swine | Mycoplasma pneumonia | Indication |
| Swine | Proliferative enteropathies (ileitis) caused by Lawsonia intracellularis | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Lincocin Tablets | Zoetis Inc. | 1 |
| Lincocin, Lincomix 25 Injectable, Lincomix 50 Injectable, Lincomix 100 Injectable, Lincomix 300 Injectable | Zoetis Inc. | 1 |
| Lincocin Aquadrops | Zoetis Inc. | 1 |
| L-S 50 Water Soluble Powder | Zoetis Inc. | 2 |
| LINCOMIX 20, LINCOMIX 50 | Zoetis Inc. | 1 |
| LINCOMIX Soluble Powder | Zoetis Inc. | 1 |
| LINCOMIX and Banminth | Phibro Animal Health Corp. | 2 |
| LINCOMIX and Banminth | Zoetis Inc. | 2 |
| SAFE-GUARD plus LINCOMIX | Intervet Inc. | 2 |
| Stenorol and LINCOMIX | Huvepharma EOOD | 2 |
| Robenz and LINCOMIX | Zoetis Inc. | 2 |
| Deccox and LINCOMIX | Zoetis Inc. | 2 |
| Bio-Cox and LINCOMIX | Zoetis Inc. | 2 |
| COYDEN and LINCOMIX | Zoetis Inc. | 2 |
| Avatec and LINCOMIX | Zoetis Inc. | 2 |
| Zoamix and LINCOMIX | Zoetis Inc. | 2 |
| Coban and LINCOMIX | Zoetis Inc. | 2 |
| Lincomycin Soluble | Huvepharma EOOD | 1 |
| Linco Soluble | Zoetis Inc. | 1 |
| Lincosol Soluble Powder | Med-Pharmex Inc. | 1 |
| Lincomycin Injectable 30% | Zoetis Inc. | 1 |
| Lincomycin Hydrochloride Soluble Powder | Quo Vademus LLC | 1 |
| Lincomycin 100, Lincomycin 25, Lincomycin 300, Lincomycin Injection 100, Lincomycin Injection 25, Lincomycin Injection 300 | Sparhawk Laboratories Inc. | 1 |
| Lincomycin - Spectinomycin | Phibro Animal Health Corp. | 2 |
| Lincomycin Injectable, USP | Huvepharma EOOD | 1 |
| LincoMed 100, LincoMed 300 | Bimeda Animal Health Limited | 1 |
| LinxMed-SP | Bimeda Animal Health Limited | 1 |
| SpecLinx-50 | Bimeda Animal Health Limited | 2 |
| Lincomycin-Spectinomycin Water Soluble Powder | Huvepharma EOOD | 2 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 12.37 | acidic |
| pKa2 | 13.98 | acidic |
| pKa3 | 8.22 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 50S ribosomal protein L10 | Ribosomal protein | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4019802 | VUID |
| N0000147891 | NUI |
| D00223 | KEGG_DRUG |
| 4018090 | VANDF |
| 4019802 | VANDF |
| C0023726 | UMLSCUI |
| CHEBI:6472 | CHEBI |
| 3QB | PDB_CHEM_ID |
| CHEMBL1447 | ChEMBL_ID |
| CHEMBL3989551 | ChEMBL_ID |
| D008034 | MESH_DESCRIPTOR_UI |
| DB01627 | DRUGBANK_ID |
| 3000540 | PUBCHEM_CID |
| 10941 | IUPHAR_LIGAND_ID |
| 1419 | INN_ID |
| 7179-49-9 | SECONDARY_CAS_RN |
| BOD072YW0F | UNII |
| 6398 | RXNORM |
| 1950 | MMSL |
| 4979 | MMSL |
| 4980 | MMSL |
| 7112 | MMSL |
| d00279 | MMSL |
| 002793 | NDDF |
| 004867 | NDDF |
| 18449009 | SNOMEDCT_US |
| 2596005 | SNOMEDCT_US |
| 372677003 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Lincocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0104 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | NDA | 27 sections |
| Lincocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0107 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | NDA | 27 sections |
| Lincocin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-0555 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | NDA | 27 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-1035 | INJECTION | 3000 mg | INTRAVENOUS | ANDA | 22 sections |
| LINCOMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9901 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 14 sections |
| LINCOMYCIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0404-9901 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 14 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-193 | INJECTION, SOLUTION | 300 mg | INTRAVENOUS | ANDA | 28 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0350 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 27 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39822-0353 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 27 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-374 | INJECTION, SOLUTION | 300 mg | INTRAVENOUS | ANDA | 22 sections |
| lincomycin hydrochloride | Human Prescription Drug Label | 1 | 68083-478 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 22 sections |
| Lincomycin hydrochloride | Human Prescription Drug Label | 1 | 68083-479 | INJECTION, SOLUTION | 300 mg | INTRAMUSCULAR | ANDA | 22 sections |
| lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-034 | INJECTION, SOLUTION | 300 mg | INTRAVENOUS | ANDA | 25 sections |
| lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70436-035 | INJECTION, SOLUTION | 300 mg | INTRAVENOUS | ANDA | 25 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72485-114 | INJECTION, SOLUTION | 600 mg | INTRAVENOUS | ANDA | 22 sections |
| Lincomycin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72485-115 | INJECTION, SOLUTION | 3000 mg | INTRAVENOUS | ANDA | 22 sections |